BioSpace News Archive

NeoImmuneTech, Inc. , a clinical-stage T cell-focused biopharmaceutical company, today announced the first patient has been dosed in a Phase 2 study of NT-I7 (efineptakin alfa), a novel long-acting human interleukin-7 (IL-7), in combination with Bristol Myers Squibb’s Opdivo® (nivolumab), a PD-1 blocking antibody, versus nivolumab monotherapy.

Members include preeminent international scientific and clinical thought leaders in gene therapy, diseases of the central nervous system, and drug discovery and development

Titan Medical Inc. announced the launch of “Titan Living Labs”, a new media-rich addition to its website providing access to the stories behind the design, engineering and innovative technologies employed by Titan’s engineering team for the Enos™ robotic single access surgical system.

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy, announced that Dr. Gil Van Bokkelen has stepped down as Chairman and Chief Executive Officer, effective immediately.

Pro forma Cash Expected to Fund Manufacturing, Regulatory and Commercial Readiness Preparations for Omidubicel and the Advancement of GDA-201 Clinical Development

FDA stated it is not currently planning to hold an advisory committee meeting Potential for Vicineum to be a best-in-class treatment with projected peak revenue of $1B-$3B globally, $400M-$900M in the US Company to hold conference call at 8am ET

For Fourth Quarter 2020, Zoetis Reports Revenue of $1.8 Billion, Growing 8%, and Net Income of $359 Million, or $0.75 per Diluted Share, on a Reported Basis Reports Adjusted Net Income of $438 Million, or Adjusted Diluted EPS of $0.91, for Fourth Quarter 2020 Delivers 9% Operational Growth in Revenue and 3% Operational Growth in Adjusted Net Income for Fourth Quarter 2020

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference 2021

Bio-Path Holdings, Inc. announced the pricing of its previously announced public offering for the offering of 1,710,600 shares of common stock at a price to the public of $7.60 per share, for aggregate gross proceeds to the Company of approximately $13.0 million, before deducting the fees and estimated offering expenses payable by the Company.

LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients.